Evidence map›Paper›PMID 42670871›Full record

ArticleJournal of chemical information and modeling2026

Uncertainty Quantification with Domain Classification Models for Acetylcholinesterase Inhibition.

Joshua S Harris, Patricia A Vignaux, Thomas R Lane, Sean Ekins

Abstract read
In one paragraph

Article in Journal of chemical information and modeling, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Joshua S HarrisCollaborations Pharmaceuticals, Inc., 1730 Varsity Drive, Suite 360, Raleigh, North Carolina27606-5228, United States.ORCID 0000-0002-2180-840X
Patricia A VignauxCollaborations Pharmaceuticals, Inc., 1730 Varsity Drive, Suite 360, Raleigh, North Carolina27606-5228, United States.ORCID 0009-0004-4015-6410
Thomas R LaneCollaborations Pharmaceuticals, Inc., 1730 Varsity Drive, Suite 360, Raleigh, North Carolina27606-5228, United States.ORCID 0000-0001-9240-4763
Sean EkinsCollaborations Pharmaceuticals, Inc., 1730 Varsity Drive, Suite 360, Raleigh, North Carolina27606-5228, United States.ORCID 0000-0002-5691-5790

Funding

Machine learning approaches to predict Acetylcholinesterase inhibition and model applicationsR44ES033855 · NIEHS · COLLABORATIONS PHARMACEUTICALS, INC. · PI EKINS, SEAN · 2024 to 2025
$2.0M
NIEHS NIH HHS 5R44ES033855-03NIEHS NIH HHS R44 ES033855
6 · The paper itself

Abstract

Uncertainty quantification is crucially important for small-molecule machine learning (ML) models. For companies and regulatory bodies that rely on ML models to inform high-cost and high-risk decisions, accurate uncertainty quantification can reveal whether a given prediction is trustworthy. Existing methods for uncertainty quantification have been shown to be less reliable outside of a model's applicability domain. We have developed a novel approach to uncertainty quantification called domain classification (DC) modeling, which combines results from three independent binary classification models to capture the relationship between the subsets of active and inactive molecules in a training set, as well as a large and diverse "out of domain" set. Applying this modeling approach to acetylcholinesterase inhibition, we show that it robustly captures aleatoric and epistemic uncertainty even for molecules far outside the applicability domain. We show that filtering predictions with uncertainty-based thresholds leads to superior prediction performance even for external test sets with significant out-of-domain character, at the cost of discarding uncertain predictions. In particular, while screening out the top 50% of uncertain predictions from a binary random forest model, recall on external test sets improves from 0.56 to 0.80, precision improves from 0.82 to 0.87, and specificity stays about the same (0.92 to 0.91). While screening out 70% of predictions, recall and precision increase to 0.91 and 0.92, respectively, while specificity stays at 0.92. Improvements in recall and precision are statistically significant with a p-value of 0.05, whereas there is no significant change in specificity. We also use DC modeling to define uncertainty windows for prediction probabilities based on confidence levels and demonstrate that these confidence levels accurately represent the likelihood that ground truth activity probabilities fall within the uncertainty window.

Indexed as

AcetylcholinesteraseCholinesterase InhibitorsMachine LearningClassification AlgorithmsPrediction AlgorithmsPredictive Learning ModelsRandom ForestUncertaintyAcetylcholinesteraseCholinesterase Inhibitors

Identifiers

PMID42670871
PMCPMC13510646

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.